logo
Plus   Neg
Share
Email

Stock Alert: Supernus Pharmaceuticals Up 14% On Positive Trial Results Of ADHD Drug

Shares of Supernus Pharmaceuticals, Inc. (SUPN) are currently gaining nearly 14%. The company on Tuesday after the bell revealed positive results from a study of its potential drug for attention deficit hyperactivity disorder, or ADHD.

SUPN is currently trading at $25.67, up $3.15 or 13.99%, on the Nasdaq.

Supernus announced that the phase 3 study of SPN-812 met the primary endpoint with robust statistical significance.

SPN-812 is under review by the U.S. Food and Drug Administration for the treatment of ADHD in pediatric patients 6 to 17 years of age. Supernus plans to ask for the drug to be considered for adults as well if it is approved by the FDA.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
The United Kingdom's Competition and Markets Authority (CMA) has launched an investigation into technology giant Apple Inc. (AAPL) following complaints that its terms and conditions for app developers are unfair and anti-competitive. iPhone maker Apple also operates the App Store, which is the only... Supermarket chain Kroger Co. on Thursday reported that it posted a loss for the fourth quarter compared to a profit last year, hurt by pension plan withdrawal liabilities. Adjusted earnings per share topped analysts' estimates, while quarterly revenues missed it. However, the company initiated adjusted earning guidance for the full-year 2021, well above analysts' estimates. Retail sales are projected to grow at a potentially record rate during 2021, but the ongoing COVID-19 pandemic remains the biggest challenge for the year, according to the National Retail Federation. "There is no doubt the economy is positioned for growth in 2021, but how much growth comes down to a single non-economic force - the coronavirus," NRF Chief Economist Jack Kleinhenz said.
RELATED NEWS
Follow RTT